|
|
Article: Palatin Partners With King On Sexual Dysfunction Candidate.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Palatin Technologies Inc. could make more than $250 million via a strategic alliance with King Pharmaceuticals Inc. for the development and commercialization of Palatin's male and female sexual dysfunction candidate, PT-141.
PT-141, a Phase II candidate, is a melanocortin receptor agonist discovered by Palatin scientists using technology developed at the University of Arizona in Tucson. While it is currently being studied in a nasal formulation, company executives said they also intend to develop it as an oral product.
Carl Spana, president and CEO of Cranbury, N.J.-based Palatin, believes the Phase II program will be completed in mid-2005, allowing the ...